2Seventy Bio Inc
NASDAQ:TSVT
2Seventy Bio Inc
Other Non-Cash Items
2Seventy Bio Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
2Seventy Bio Inc
NASDAQ:TSVT
|
Other Non-Cash Items
-$37.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Non-Cash Items
$10.4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Non-Cash Items
$10.3B
|
CAGR 3-Years
55%
|
CAGR 5-Years
14%
|
CAGR 10-Years
36%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Non-Cash Items
$671m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
41%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Non-Cash Items
$699.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
31%
|
CAGR 10-Years
15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Non-Cash Items
$900.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
2Seventy Bio Inc
Glance View
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.
See Also
What is 2Seventy Bio Inc's Other Non-Cash Items?
Other Non-Cash Items
-37.8m
USD
Based on the financial report for Dec 31, 2024, 2Seventy Bio Inc's Other Non-Cash Items amounts to -37.8m USD.
You don't have any saved screeners yet